SCHEMBL2068328

SCHEMBL2068328

Cc1ncc(Br)cc1CCN

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 3/20 0.41
HRH4 Q9H3N8 3/20 0.41
TAAR1 Q96RJ0 7/20 0.37
HTR2A P28223 3/20 0.37
HTR2C P28335 1/20 0.37
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.33
HRH2 P25021 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
MEN1 O00255 1/20 0.32
GAPDH P04406 1/20 0.32
THRB P10828 1/20 0.32
APEX1 P27695 1/20 0.32
RAD52 P43351 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2066694 0.84 HTT (0.39) HRH1HRH4KMT2AHTTSMN1; SMN2
SCHEMBL25696363 0.82 SMN1; SMN2 (0.34) KMT2AHTTSMN1; SMN2LMNARECQL
SCHEMBL30403001 0.82 SMN1; SMN2 (0.34) KMT2AHTTSMN1; SMN2LMNARECQL
SCHEMBL15699752 0.78 SMN1; SMN2 (0.36) KMT2AHTTSMN1; SMN2
SCHEMBL17427757 0.78 NOS3 (0.39) KMT2AHTTSMN1; SMN2
SCHEMBL2066886 0.77 KMT2A (0.36) HRH1HRH4TAAR1HTR2AHTR2C
SCHEMBL2067183 0.77 TAAR1 (0.37) HRH1HRH4TAAR1HTR2AHTR2C
SCHEMBL31145165 0.76 KDM4E (0.46) KMT2AHTTSMN1; SMN2LMNAMEN1
SCHEMBL15004184 0.76 KDM4E (0.46) KMT2AHTTSMN1; SMN2LMNAMEN1
SCHEMBL22771018 0.76 SMN1; SMN2 (0.35) KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
CN-102803259-A 1H-Imidazo[4, 5-c]quinolinone compounds, useful for the treatment of proliferative diseases NOVARTIS AG 2012-11-28 CN disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 HRH1 861/4885HRH4 849/4885TAAR1 3913/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 HRH1 946/4885HRH4 920/4885TAAR1 3825/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 HRH1 946/4885HRH4 920/4885TAAR1 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.